摘要
新生血管性年龄相关性黄斑变性(nAMD)、糖尿病视网膜病变(DR)等眼底病继发形成新生血管,是致盲的重要原因之一。抗血管内皮生长因子(VEGF)治疗是当前主流疗法。但仍存在部分患者对其疗效欠佳等局限,临床仍需要开发新的药物靶点。
The appearance of new blood vessels in the neovascular age-related macular degeneration(nAMD),diabetic retinopathy(DR),and other ocular diseases is one of the important reasons for blindness.Anti-vascular endothelial growth factor(VEGF)drugs are the current mainstream.However,some patients have poor efficacy and other adverse reactions.There is still a need to develop new drugs.
作者
刘辰
方思尹
顾操
吴晋晖
LIU Chen;FANG Si-yin;GU Cao;WU Jin-hui(Department of Ophthalmology, the First Affiliated Hospital, Navy Military Medical University, Shanghai 200433;Department of Ophthalmology, the Third Affiliated Hospital, Navy Military Medical University,Shanghai 200438, China)
出处
《基础医学与临床》
2022年第2期325-329,共5页
Basic and Clinical Medicine
基金
上海市浦江人才项目(17PJD041)
海军军医大学,未来战争医学防护技术研发专项(19WLMS-03)
上海市中医药管理局(ZHYY-ZXYJHZX-202024)。
